source
- Servier’s $1.55 billion Becker muscular dystrophy drug fails pivotal Phase 3 trialServier announced that its experimental drug for Becker muscular dystrophy did not meet its primary endpoint in a Phase 3 trial called GRAND CANYON. The drug, sevasemten, was acquired from Edgewis…
- Pfizer raises 2026 outlook as oncology and migraine growth balances Covid product declinePfizer announced it has increased its financial guidance for 2026, citing stronger performance in its cancer and migraine divisions. The company said sales of its Covid-19 related products have fa…